Alisporivir - Debiopharm

Drug Profile

Alisporivir - Debiopharm

Alternative Names: DEB-025; DEBIO-025; DEBIO-25

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Debiopharm
  • Developer Debiopharm; Solid Biosciences
  • Class Ciclosporins
  • Mechanism of Action Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hepatitis C
  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Apr 2016 Novartis terminates phase III trial in Hepatitis C (combination therapy, treatment-naive African American patients) in USA (NCT01446250)
  • 08 Sep 2015 Debiopharm International and Solid Biosciences collaborated to co-develop alisporivir for Duchenne muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top